Guardant Health, Inc.

Guardant Health's Board approved performance-based restricted stock units (PSUs) for its Co-CEOs, Helmy Eltoukhy and AmirAli Talasaz. Each received 465,413 target PSUs, with vesting tied to the company's total shareholder return (TSR) relative to the S&P 500 over three- and five-year periods. The awards are designed to align executive compensation with long-term stockholder value creation and market-leading performance.

Guardant Health reported a significant increase in revenue for the second quarter of 2026, reaching $334.98 million, a 44.3% rise year-over-year. However, the company's net loss also widened to $120.14 million for the quarter. Key business developments include the FDA approval of its Guardant360 Liquid CDx test and the Shield blood test for primary colorectal cancer screening, which also meets Medicare coverage requirements.

Guardant Health reported strong second quarter 2026 financial results, with total revenue increasing 44% year-over-year to $335.0 million, driven by significant growth in both Oncology and Screening segments. The company raised its full year 2026 revenue guidance to a range of $1.34 billion to $1.36 billion, reflecting increased expectations for oncology and screening volumes. Key operational milestones included multiple FDA approvals for Guardant360 products and the inclusion of Shield in American Cancer Society guidelines, alongside new coverage from UnitedHealth Group.

Guardant Health reported a significant increase in revenue for the first quarter ended March 31, 2026, reaching $301.7 million, a 48.3% rise year-over-year. This growth was primarily driven by strong performance in oncology and a substantial surge in screening revenue. However, the company's net loss also expanded to $(112.1) million, up from $(95.2) million in the same period last year, resulting in a diluted net loss per share of $(0.85).

Guardant Health reported strong first-quarter 2026 financial results, with total revenue increasing 48% year-over-year to $301.7 million. This growth was driven by significant increases in Oncology revenue (+36%) and Screening revenue (over 600%). The company also raised its full-year 2026 revenue guidance to $1.30 to $1.32 billion, representing 32% to 34% growth, up from prior guidance. Operating highlights included FDA approval for Guardant360 CDx and new collaborations.

Guardant Health, Inc. announced the resignation of its Chief Medical Officer, Craig Eagle, M.D. His departure will be effective on May 8, 2026.